期刊
PSYCHOPHARMACOLOGY
卷 231, 期 15, 页码 3009-3017出版社
SPRINGER
DOI: 10.1007/s00213-014-3478-5
关键词
Alzheimer's disease; Novel therapeutic; Cannabidiol; Transgenic APP(swe)/PS1 Delta E9 mice; Cognition; Behaviour; Social recognition memory; Object recognition memory
资金
- Schizophrenia Research Institute
- NSW Ministry of Health
- Motor Neuron Disease Research Institute of Australia
- National Health and Medical Research Council (NHMRC) [1045643]
- Australian Research Council [FT0991986]
- NHMRC [1003886]
- Australian Postgraduate Award scholarship from the University of New South Wales
- Neuroscience Research Australia
- Australian Research Council [FT0991986] Funding Source: Australian Research Council
Patients suffering from Alzheimer's disease (AD) exhibit a decline in cognitive abilities including an inability to recognise familiar faces. Hallmark pathological changes in AD include the aggregation of amyloid-beta (A beta), tau protein hyperphosphorylation as well as pronounced neurodegeneration, neuroinflammation, neurotoxicity and oxidative damage. The non-psychoactive phytocannabinoid cannabidiol (CBD) exerts neuroprotective, anti-oxidant and anti-inflammatory effects and promotes neurogenesis. CBD also reverses A beta-induced spatial memory deficits in rodents. Thus we determined the therapeutic-like effects of chronic CBD treatment (20 mg/kg, daily intraperitoneal injections for 3 weeks) on the APP(swe)/PS1a dagger E9 (APPxPS1) transgenic mouse model for AD in a number of cognitive tests, including the social preference test, the novel object recognition task and the fear conditioning paradigm. We also analysed the impact of CBD on anxiety behaviours in the elevated plus maze. Vehicle-treated APPxPS1 mice demonstrated impairments in social recognition and novel object recognition compared to wild type-like mice. Chronic CBD treatment reversed these cognitive deficits in APPxPS1 mice without affecting anxiety-related behaviours. This is the first study to investigate the effect of chronic CBD treatment on cognition in an AD transgenic mouse model. Our findings suggest that CBD may have therapeutic potential for specific cognitive impairments associated with AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据